Bimat is a brand-name ophthalmic solution that contains bimatoprost as its sole active ingredient. Bimatoprost belongs to the prostaglandin analog class of eye-care medications and is formulated as a clear liquid supplied in a 3 ml bottle. In Hong Kong, Bimat is classified as a prescription-only product and is regulated by the Hong Kong Department of Health, Pharmacy Division. It is primarily prescribed to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Bimatoprost mimics the activity of naturally occurring prostaglandin F₂α. When administered as a single drop into the eye, it:
The medication begins to lower IOP within a few hours of the first dose, reaches peak effect after about 8-12 hours, and maintains a therapeutic effect for 24 hours, which is why once-daily dosing is sufficient for most patients.
Bimat is FDA- and EMA-approved (and similarly approved by Hong Kong health authorities) for the following indications:
These indications apply to adult patients, typically those 18 years of age and older, who require pharmacologic IOP reduction to preserve visual function.
Bimatoprost has been studied for its ability to promote eyelash growth. This effect is not approved for the treatment of any eyelash condition by regulatory agencies in Hong Kong, the United States, or the European Union.
Disclaimer: Off-label use of bimatoprost for cosmetic eyelash enhancement should only be undertaken under the supervision of a qualified ophthalmologist or dermatologist, with a personalized risk-benefit assessment.
If any of these serious signs develop, discontinue Bimat and contact an eye-care professional promptly.
Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their ophthalmologist before starting Bimat.
Bimatoprost is administered topically to the eye, so food intake does not affect its absorption. However:
This article provides educational information about Bimat and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. The usual regimen involves instilling one drop in each affected eye once daily, unless the prescribing clinician advises otherwise.
Persistent hyperemia may indicate irritation or an allergic response. Continue using the medication as directed for a few days; if redness persists beyond a week or worsens, schedule an appointment with your ophthalmologist.
Remove contact lenses before instilling Bimat. Wait at least 15 minutes after the drop is administered before reinserting lenses to ensure adequate drug absorption and to avoid contaminating the lenses.
Some patients notice brief blurred vision or a mild visual disturbance shortly after application, usually resolving within minutes. If the effect lasts longer or is accompanied by pain, seek medical advice.
Artificial tears can be used, but apply them at least 5 minutes apart from Bimat to prevent dilution of the prostaglandin analog.
Bimatoprost can increase melanin production in iris stromal cells, leading to a permanent darkening of the eye color. This effect is more noticeable in individuals with lighter-colored eyes.
No specific dietary restrictions are required, as Bimat is administered topically. However, maintain a balanced diet to support overall ocular health.
A single 3 ml bottle provides approximately 90 days of treatment when using one drop per eye daily. The actual duration may vary slightly based on drop size and usage pattern.
Prostaglandin analogs may increase the risk of cystoid macular edema after intraocular surgery. Your surgeon will determine the appropriate timing for initiating Bimat post-operatively.
Coverage depends on the specific formulary and eligibility criteria set by the Hospital Authority. Patients should consult their prescribing clinic or pharmacy for details on subsidy or reimbursement options.
